We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people wh... Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia. Show more
- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses...
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.016 | -3.48583877996 | 0.459 | 0.4749 | 0.401 | 94282 | 0.4316864 | CS |
4 | -0.0433 | -8.90396874357 | 0.4863 | 0.58 | 0.401 | 186518 | 0.4952413 | CS |
12 | 0.023 | 5.47619047619 | 0.42 | 0.6288 | 0.279 | 313172 | 0.4327987 | CS |
26 | -0.0711 | -13.8299941646 | 0.5141 | 1.04 | 0.279 | 396011 | 0.59497916 | CS |
52 | -0.487 | -52.3655913978 | 0.93 | 2.42 | 0.279 | 537508 | 1.05265996 | CS |
156 | -5.167 | -92.1033868093 | 5.61 | 9.1109 | 0.218951 | 494756 | 1.08829447 | CS |
260 | -13.317 | -96.7805232558 | 13.76 | 14.39 | 0.218951 | 474679 | 1.57307111 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions